Sera Prognostics Inc-a (SERA)
$7.21
+0.29
(+4.19%)▲
Performance
- $6.95$7.23$7.21
3.68%
Downside
Day's Volatility :3.94%
Upside
0.28%
- $1.56$12.36$7.21
78.36%
Downside
52 Weeks Volatility :87.37%
Upside
41.64%
Returns
| Period | Sera Prognostics Inc-a | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 28.39% | 5.7% | 0.0% |
6 Months | -26.23% | 6.7% | 0.0% |
1 Year | 195.73% | 18.4% | 0.0% |
3 Years | -37.49% | 20.8% | -20.2% |
Highlights
Market Capitalization | 249.6M |
Book Value | $1.79 |
Earnings Per Share (EPS) | -0.98 |
Wall Street Target Price | 2.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -38554.17% |
Return On Assets TTM | -24.36% |
Return On Equity TTM | -44.77% |
Revenue TTM | 107.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -80.5% |
Gross Profit TTM | 75.0K |
EBITDA | -34.5M |
Diluted Eps TTM | -0.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.97 |
EPS Estimate Next Year | -0.97 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 61.86%
Technicals Summary
Sell
Neutral
Buy
Sera Prognostics Inc-a is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Sera Prognostics Inc-a | -6.61% | -26.23% | 195.73% | -37.49% | -41.85% |
 Stryker Corporation | -2.41% | 1.22% | 32.08% | 34.03% | 63.17% |
 Boston Scientific Corp. | 2.27% | 23.72% | 62.6% | 97.64% | 106.81% |
 Edwards Lifesciences Corp. | -5.16% | -28.32% | -8.28% | -38.54% | -14.51% |
 Abbott Laboratories | -1.9% | 1.93% | 17.33% | -2.86% | 36.88% |
 Medtronic Plc | -3.58% | 4.59% | 15.08% | -29.81% | -19.15% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Sera Prognostics Inc-a | NA | NA | NA | -0.97 | -0.45 | -0.24 | NA | 1.79 |
Stryker Corporation | 39.2 | 39.2 | 2.58 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 68.15 | 68.15 | 2.06 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 25.74 | 25.74 | 3.44 | 2.62 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.52 | 35.52 | 4.1 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
Medtronic Plc | 30.31 | 30.31 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Sera Prognostics Inc-a | Buy | $249.6M | -41.85% | NA | 0.0% |
Stryker Corporation | Buy | $135.3B | 63.17% | 39.2 | 16.12% |
Boston Scientific Corp. | Buy | $124.4B | 106.81% | 68.15 | 12.0% |
Edwards Lifesciences Corp. | Buy | $39.4B | -14.51% | 25.74 | 23.74% |
Abbott Laboratories | Buy | $195.3B | 36.88% | 35.52 | 13.65% |
Medtronic Plc | Buy | $115.5B | -19.15% | 30.31 | 12.06% |
Insights on Sera Prognostics Inc-a
Decreasing Revenue
Revenue is down for the last 4 quarters, 123.0K → 24.0K (in $), with an average decrease of 36.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -7.21M → -8.30M (in $), with an average decrease of 4.9% per quarter
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 97.6% return, outperforming this stock by 135.1%
Institutional Holdings
Baker Bros Advisors LP
16.29%RA Capital Management, LLC
9.09%Vivo Capital, LLC
4.95%BlackRock Inc
4.23%Vanguard Group Inc
3.32%Geode Capital Management, LLC
1.61%
Company Information
sera prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. the company has assembled a strong management team and board of directors with significant clinical development and women’s healthcare diagnostic experience. the company is supported by a strong group of investors, including the bill & melinda gates foundation, chione, ltd, domain associates, interwest partners, catalyst health ventures, upstart life sciences capital, and osage university partners. the company is working with the bill & melinda gates foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. sera prognostics is located in salt lake city, utah. sera launched its first diagnos
Organization | Sera Prognostics Inc-a |
Employees | 55 |
CEO | Ms. Evguenia Lindgardt M.B.A. |
Industry | Services |
